Skip to content

Study · Systematic review · 2021

2 results

Effects of Antidiabetic Drugs on Muscle Mass in Type 2 Diabetes Mellitus.

Ida S, Kaneko R, Imataka K, Okubo K, Shirakura Y, Azuma K, Fujiwara R, Murata K

Current diabetes reviews1 Jan 2021Cited by 67 (Europe PMC)

PMID32628589 (opens in a new tab)DOI10.2174/1573399816666200705210006 (opens in a new tab)PepBankPUB-32628589
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, semaglutide significantly decreased fat-free mass compared with placebo (MD -1.68).

    In plain wordsIn adults with type 2 diabetes, semaglutide reduced fat-free mass (a measure of muscle) more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseFat-free mass change
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Semaglutide (MD: -1.68, 95% CI: -2.84 to -0.52)
    2 context sentences
    Summary · context
    To comparatively examine the effects of GLP-1RAs and oral antidiabetic drugs, including SGLT2 inhibitors and metformin, on muscle mass and body weight in patients with type 2 diabetes via a network meta-analysis of randomized controlled trials.
    Summary · context
    Of the studies identified, 18 randomized controlled trials (1, 363 subjects) satisfied the eligibility criteria.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, semaglutide produced significant weight loss compared with placebo.

    In plain wordsIn adults with type 2 diabetes, semaglutide led to more weight loss than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight loss
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    When compared with the placebo, semaglutide, dapagliflozin, ipragliflozin, and canagliflozin showed a significant weight loss.
    2 context sentences
    Summary · context
    To comparatively examine the effects of GLP-1RAs and oral antidiabetic drugs, including SGLT2 inhibitors and metformin, on muscle mass and body weight in patients with type 2 diabetes via a network meta-analysis of randomized controlled trials.
    Summary · context
    Of the studies identified, 18 randomized controlled trials (1, 363 subjects) satisfied the eligibility criteria.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.